艾迪药业2025年度营业总收入7.21亿元 同比增加72.49%

Core Viewpoint - Eddie Pharmaceutical (688488.SH) reported a significant increase in total revenue for the fiscal year 2025, with total revenue reaching 721 million yuan, representing a year-on-year increase of 72.49%. However, the net profit attributable to the parent company was a loss of 19.73 million yuan, although the loss margin decreased by 86.02% compared to the previous year [1]. Financial Performance - Total revenue for the reporting period was 721 million yuan, marking a 72.49% increase year-on-year [1]. - The net profit attributable to the parent company was a loss of 19.73 million yuan, with the loss margin decreasing by 86.02% compared to the same period last year [1]. Revenue Drivers - The increase in revenue was primarily driven by higher income from innovative anti-HIV drugs and the operational data from the merger with Nanda Pharmaceutical, which contributed approximately 25.5 million yuan to the gross profit of the main business compared to the previous year [1]. Expense Analysis - Sales expenses increased by approximately 9.2 million yuan year-on-year due to intensified promotion efforts for new drugs and the operational data from the merger with Nanda Pharmaceutical [1]. - Asset impairment losses decreased by approximately 4.8 million yuan year-on-year, as market expansion and expectations stabilized during the reporting period [1].